SINOVAC BIOTECH LTD. Risk Report

⚖️ Legal & Regulatory

Sinovac Biotech is currently navigating multiple legal disputes, which might influence its governance and shareholder confidence. The company has been embroiled in a contentious proxy battle, as well as various lawsuits, some of which have implications for the company's control and governance. Legal outcomes in these cases could significantly impact Sinovac's operational strategies and shareholder value.

• The Eastern Caribbean Supreme Court supported the right of Prime Success and Vivo Capital to participate in Sinovac's critical shareholder vote 🗓 July 9, 2025.
• An appeal decision from the eastern caribbean supports major shareholders in Sinovac's vote dispute 🗓 July 9, 2025.
• Saif Partners initiated a legal filing with definitive proxy materials for a special meeting 🗓 June 16, 2025.
• Vivo Capital launched lawsuits against Sinovac's board actions, alleging value-destructive decisions 🗓 April 24, 2025.

🏅 Awards & Recognition

Sinovac Biotech has recently received endorsements and validations that bolster its standing in the vaccine industry. Notably, the company has achieved recognition for both its products and governance, despite ongoing challenges.

• Sinovac's COVID-19 vaccine was validated by WHO for emergency use, ensuring credibility and increasing global demand 🗓 June 1, 2021.
• The company's polio vaccine secured WHO prequalification, enhancing its product portfolio and market credibility 🗓 June 9, 2022.